2025 Q3 -tulosraportti
19 päivää sitten0,0823 SEK/osake
Viimeisin osinko
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
41 251
Myynti
Määrä
42 782
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 337 | - | - | ||
| 3 193 | - | - | ||
| 191 | - | - | ||
| 83 | - | - | ||
| 5 022 | - | - |
Ylin
22,65VWAP
Alin
21,25VaihtoMäärä
23,2 1 044 586
VWAP
Ylin
22,65Alin
21,25VaihtoMäärä
23,2 1 044 586
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 28.5. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 28.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·14 t sittenSanionas pipeline. The top 3 are what Saniona will continue with, with proof of concept, and there is a potential mega seller among them…..guess which one…..? Furthermore, the two products are marked with a green arrow, for new partnerships….. Tesofine (medix) I count as a wildcard, plus if it gets approved, but great uncertainty (and a long time coming) so it is also partially included with risk of a negative outcome in the current price. Of course down 10~20 percent down upon rejection, but I think it will relatively quickly go up again. Upside upon approval, might be in the same range, 10~20 % up….. is my guess. I am convinced that Saniona is still undervalued at the current price. What do others think?
·11 t sittenI don't believe it will only yield 10-20%. It might only be Mexico, but there were several other countries that would have been interesting. Also, consider a small Swedish biotech company has one of the first obesity pills, and royalties coming in every month. It will yield much more. But what it will yield, I won't even venture a guess. Furthermore, I would guess the price will be 400 DKK per month, meaning they need approximately 100,000 users to earn 100 million in royalties. That's approximately 0.5% of the obese population in Mexico. I think that's set very low, and yes, I know it's a poor country. Regarding a rejection, which I don't believe in at all, as it doesn't make sense to drag it out for so long. Plus, they have been positive about it. There's nothing else to do but wait, but I personally see it as a bonus.
·11.12.Stig B where are you ?
·1 päivä sitten · MuokattuHallelujah - just discovered I/we still have 4,900 pcs in one of my wife's depots :-) - with the 500 I just repurchased at 18.17 for "sentimental" reasons, I only need 4,600 more to have the 10,000 I might have wanted to keep - so we'll see what I will/can get for them :-). Have a good Sunday- ·8.12.Now we will go a bit sideways for some days where many small investors will exit.·10.12.Yes, and then we just need the 100% approval from him podium, it was already approved several years ago and many, many times throughout those years and even more approved at the end of October. 😉👍 again a huge misfire from him But yes, let's continue 5-6% sideways while it gets approved 🙄🙄🙄🙄
5.12.5.12.what drives this uptrend? I stopped out·5.12.Since they released their financial report, it's as if people have become aware that they also just received money from the Jazz agreement, even though it has been known for a long time, but now people could see it in the financial report that there was approximately 700 million in cash. The company is still undervalued in my opinion. They sold a preclinical product to Jazz for an insane amount, yes, they have 3 of those they will run internally. As well as 2 major agreements, and a trigger like tesofensine. Besides that, some funds have bought and they will be included in many Indices from Dec 22. That means they must have bought before that date. Look further down in the debate. 👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
19 päivää sitten0,0823 SEK/osake
Viimeisin osinko
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenSanionas pipeline. The top 3 are what Saniona will continue with, with proof of concept, and there is a potential mega seller among them…..guess which one…..? Furthermore, the two products are marked with a green arrow, for new partnerships….. Tesofine (medix) I count as a wildcard, plus if it gets approved, but great uncertainty (and a long time coming) so it is also partially included with risk of a negative outcome in the current price. Of course down 10~20 percent down upon rejection, but I think it will relatively quickly go up again. Upside upon approval, might be in the same range, 10~20 % up….. is my guess. I am convinced that Saniona is still undervalued at the current price. What do others think?·11 t sittenI don't believe it will only yield 10-20%. It might only be Mexico, but there were several other countries that would have been interesting. Also, consider a small Swedish biotech company has one of the first obesity pills, and royalties coming in every month. It will yield much more. But what it will yield, I won't even venture a guess. Furthermore, I would guess the price will be 400 DKK per month, meaning they need approximately 100,000 users to earn 100 million in royalties. That's approximately 0.5% of the obese population in Mexico. I think that's set very low, and yes, I know it's a poor country. Regarding a rejection, which I don't believe in at all, as it doesn't make sense to drag it out for so long. Plus, they have been positive about it. There's nothing else to do but wait, but I personally see it as a bonus.
- ·11.12.Stig B where are you ?·1 päivä sitten · MuokattuHallelujah - just discovered I/we still have 4,900 pcs in one of my wife's depots :-) - with the 500 I just repurchased at 18.17 for "sentimental" reasons, I only need 4,600 more to have the 10,000 I might have wanted to keep - so we'll see what I will/can get for them :-). Have a good Sunday
- ·8.12.Now we will go a bit sideways for some days where many small investors will exit.·10.12.Yes, and then we just need the 100% approval from him podium, it was already approved several years ago and many, many times throughout those years and even more approved at the end of October. 😉👍 again a huge misfire from him But yes, let's continue 5-6% sideways while it gets approved 🙄🙄🙄🙄
- 5.12.5.12.what drives this uptrend? I stopped out·5.12.Since they released their financial report, it's as if people have become aware that they also just received money from the Jazz agreement, even though it has been known for a long time, but now people could see it in the financial report that there was approximately 700 million in cash. The company is still undervalued in my opinion. They sold a preclinical product to Jazz for an insane amount, yes, they have 3 of those they will run internally. As well as 2 major agreements, and a trigger like tesofensine. Besides that, some funds have bought and they will be included in many Indices from Dec 22. That means they must have bought before that date. Look further down in the debate. 👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
41 251
Myynti
Määrä
42 782
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 337 | - | - | ||
| 3 193 | - | - | ||
| 191 | - | - | ||
| 83 | - | - | ||
| 5 022 | - | - |
Ylin
22,65VWAP
Alin
21,25VaihtoMäärä
23,2 1 044 586
VWAP
Ylin
22,65Alin
21,25VaihtoMäärä
23,2 1 044 586
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 28.5. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 28.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
19 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 28.5. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 28.11.2024 |
Datan lähde: FactSet, Quartr
0,0823 SEK/osake
Viimeisin osinko
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenSanionas pipeline. The top 3 are what Saniona will continue with, with proof of concept, and there is a potential mega seller among them…..guess which one…..? Furthermore, the two products are marked with a green arrow, for new partnerships….. Tesofine (medix) I count as a wildcard, plus if it gets approved, but great uncertainty (and a long time coming) so it is also partially included with risk of a negative outcome in the current price. Of course down 10~20 percent down upon rejection, but I think it will relatively quickly go up again. Upside upon approval, might be in the same range, 10~20 % up….. is my guess. I am convinced that Saniona is still undervalued at the current price. What do others think?·11 t sittenI don't believe it will only yield 10-20%. It might only be Mexico, but there were several other countries that would have been interesting. Also, consider a small Swedish biotech company has one of the first obesity pills, and royalties coming in every month. It will yield much more. But what it will yield, I won't even venture a guess. Furthermore, I would guess the price will be 400 DKK per month, meaning they need approximately 100,000 users to earn 100 million in royalties. That's approximately 0.5% of the obese population in Mexico. I think that's set very low, and yes, I know it's a poor country. Regarding a rejection, which I don't believe in at all, as it doesn't make sense to drag it out for so long. Plus, they have been positive about it. There's nothing else to do but wait, but I personally see it as a bonus.
- ·11.12.Stig B where are you ?·1 päivä sitten · MuokattuHallelujah - just discovered I/we still have 4,900 pcs in one of my wife's depots :-) - with the 500 I just repurchased at 18.17 for "sentimental" reasons, I only need 4,600 more to have the 10,000 I might have wanted to keep - so we'll see what I will/can get for them :-). Have a good Sunday
- ·8.12.Now we will go a bit sideways for some days where many small investors will exit.·10.12.Yes, and then we just need the 100% approval from him podium, it was already approved several years ago and many, many times throughout those years and even more approved at the end of October. 😉👍 again a huge misfire from him But yes, let's continue 5-6% sideways while it gets approved 🙄🙄🙄🙄
- 5.12.5.12.what drives this uptrend? I stopped out·5.12.Since they released their financial report, it's as if people have become aware that they also just received money from the Jazz agreement, even though it has been known for a long time, but now people could see it in the financial report that there was approximately 700 million in cash. The company is still undervalued in my opinion. They sold a preclinical product to Jazz for an insane amount, yes, they have 3 of those they will run internally. As well as 2 major agreements, and a trigger like tesofensine. Besides that, some funds have bought and they will be included in many Indices from Dec 22. That means they must have bought before that date. Look further down in the debate. 👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
41 251
Myynti
Määrä
42 782
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 337 | - | - | ||
| 3 193 | - | - | ||
| 191 | - | - | ||
| 83 | - | - | ||
| 5 022 | - | - |
Ylin
22,65VWAP
Alin
21,25VaihtoMäärä
23,2 1 044 586
VWAP
Ylin
22,65Alin
21,25VaihtoMäärä
23,2 1 044 586
Välittäjätilasto
Dataa ei löytynyt